The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 40.00
Ask: 41.00
Change: -1.30 (-3.11%)
Spread: 1.00 (2.50%)
Open: 40.50
High: 40.50
Low: 40.50
Prev. Close: 41.80
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of AGM

20 Jun 2022 14:31

RNS Number : 5172P
Venture Life Group PLC
20 June 2022
 

20 June 2022

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Results of AGM

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, held its Annual General Meeting ("AGM") earlier today at the offices of Simmons & Simmons LLP, CityPoint, 1 Ropemaker St, London EC2V 9HT.

Ordinary resolutions 1 to 5 were duly passed together with special resolution 7. Special resolution 6 was not passed. Proxy votes were received in respect of approximately 68% of the Company's issued share capital and the final votes received in respect of each resolution were as follows:

Resolution

Number of votes for

% Votes for

Number of votes against

% Votes against

Number of votes withheld

1. To receive and adopt the reports of the Directors and auditor and the audited accounts of the Company for the year ended 31 December 2021

 

84,876,146

99.41%

500,565

0.59%

1,000

2. To re-elect as a Director, Sharon Daly (nee Collins), who seeks re-election

85,354,797

99.97%

21,513

0.03%

1,401

3. To appoint Daniel Wells as a Director of the Company

85,354,797

99.97%

21,513

0.03%

1,401

4. To appoint Paul McGreevy as Non-Executive Director and Chair of the Company

85,350,997

99.97%

25,313

0.03%

1,401

5. The Directors are authorised to allot shares in the Company

63,554,349

74.44%

21,822,362

25.56%

1,000

6. The Directors are authorised to allot equity securities for cash

65,519,931

74.40%

21,856,780

25.60%

1,000

7. The Company is authorised to make one or more market purchases of ordinary shares

85,355,463

99.97%

22,248

0.03%

-

For further information, please contact:

 

Venture Life Group PLC +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20 74963000

Jonathan Dighe (Sales)

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBKKBBNBKDCAB
Date   Source Headline
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement
22nd Jun 201612:35 pmRNSResult of AGM
14th Jun 201612:18 pmRNSDirector/PDMR Shareholding
17th May 20164:17 pmRNSDirector/PDMR Shareholding
9th May 20161:13 pmRNSDirector/PDMR Shareholding
9th May 20167:00 amRNSAnnual Financial Report
4th May 20167:00 amRNSFinal Results
3rd May 20167:00 amRNSFirst distribution agreements signed for UltraDEX
31st Mar 20167:00 amRNSDistribution Deals on Benecol 'once a day' Sachet
29th Mar 20167:02 amRNSNotice of Results
18th Mar 201611:04 amRNS'1000 Companies to Inspire Britain 2016' report
7th Mar 20167:00 amRNSCompletion of Acquisition
3rd Mar 20167:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.